A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
一项 1 期剂量递增研究，旨在评估 AsiDNA（一种首创的 DNA 修复抑制剂）在晚期实体瘤患者中静脉注射给药的安全性、药代动力学和药效学。
期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-020-01028-8
Le Tourneau, Christophe; Delord, Jean-Pierre; Kotecki, Nuria; Borcoman, Edith; Gomez-Roca, Carlos; Hescot, Ségolène; Jungels, Christiane; Vincent-Salomon, Anne; Cockenpot, Vincent; Eberst, Lauriane; Molé, Audrey; Jdey, Wael; Bono, Françoise; Trochon-Joseph, Véronique; Toussaint, Hélène; Zandanel, Christelle; Adamiec, Olga; de Beaumont, Olivier; Cassier, Philippe Alexandre
